Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

Rezultati

Naziv:	Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study
Autori :	Nabors, Louis Burt; ...; Grujicic, Danica M; ...; (broj, koautora 17)
Godina:	2015
Publikacija:	NEURO-ONCOLOGY
ISSN:	1522-8517 Neuro-oncology Pretraži identifikator
Tip rezultata:	Naučni članak
Kolacija:	vol. 17 br. 5 str. 708-717
DOI:	10.1093/neuonc/nou356
WoS-ID:	000356263100011
Scopus-ID:	2-s2.0-84928882474
PMID:	25762461
PMCID:	PMC4482861
URI:	https://enauka.gov.rs/handle/123456789/807063
Projekat:	Merck KGaA, Darmstadt, Germany
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

210
SCOPUS^TM

136
PubMed Central^TM

147
OpenCitations

196
WEB OF SCIENCE^TM

Alt metrika

Dimensions

Unpaywall

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.